Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The Rheumatic Fever Market faces a crucial role in responding to the disease that comes from untreated or inadequately treated streptococcal infections primarily affecting children and adolescents. It is an inflammatory response disorder leading to involvement of several body parts especially the heart, joints, skin and brain. Both prevention and management of rheumatic fever are important in the market due to its long-term health consequences such as rheumatic heart disease. This involves early administration of antibiotics including penicillin for treatment of streptococcal infection.
Pharmaceutical interventions also occupy significant space in the Rheumatic Fever Market which highlights the importance of antibiotics in fighting streptococcus infections beneath. The prevention of these infections becoming rheumatic fever greatly relies on immediate treatment with effective antibiotics. Moreover, non-steroidal anti-inflammatory drugs (NSAIDs) are given for its remedial functions and minimizing inflammation among affected people. In addition, it seeks timely and appropriate pharmaceutical interventions with a view towards preventing recurrences of RF episodes as well as mitigating associated health risks.
Rheumatic heart disease – a grave complication resulting from recurring attacks – lays emphasis on continuous cardiac care within this market environment. Consequently, monitoring and managing cardiac symptoms like valvular damage are central part of treatment strategy. Some cases may involve surgical procedures such as valve repairs or changes when they are complicated further. Therefore, this requires cardiology experts who work together with other healthcare providers like rheumatologists so that comprehensive care can be availed for people having it.
From a geographical perspective, Rheumatic Fever Market reaches out to areas having high incidences of streptococcal infections but limited access to healthcare services. While it has become less prevalent in developed countries, there remain high rates of rheumatic fever in certain regions within Africa Asia Pacific and Oceania groupings; hence, these disparities have been addressed by improving healthcare infrastructure; creating awareness and making essential drugs available in areas constrained by resources.
Nevertheless, the Rheumatic Fever Market is faced with several challenges including a disease that involves multiple organs and systems. The long-term effects on individuals, majorly regarding heart health require continuous monitoring and care. Additionally, ensuring access to healthcare services and medications pose as a hindrance within the market particularly in areas where there are scarce resources.
For this reason, going forward the Rheumatic Fever Market is expected to continue preventing its occurrence, early diagnosing as well as managing it comprehensively. It also seeks for further research on pathogenesis of RF known better and explore possible treatment enhancement options. In this regard, the industry has shown commitment towards addressing such social determinants of health like education and provision of medical facilities hence reducing global burden of RF including all its attendant complications.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Growth Rate | Â Â 4.60% CAGR |
Rheumatic Fever Market Highlights:
Global Rheumatic Fever Market Overview
Rheumatic Fever Market Size was valued at USD 0.23 Billion in 2023. The Global Rheumatic Fever industry is projected to grow from USD 0.36 Billion in 2024 to USD 1.37 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.82% during the forecast period (2024 - 2032).
Rheumatic fever is an autoimmune inflammatory disease which can develop as a complication of inadequately treated strep throat. Strep throat is a condition caused by group a Streptococcus bacterium. Rheumatic fever is common in the age group of 5 to 15 years, but adults can also have the condition. In certain cases, rheumatic fever can cause long-term damage to the heart and heart valves.
The increasing occurrences of strep throat and growing prevalence of rheumatic heart disease are expected to be the major drivers for the growth of the market during the forecast period. Moreover, increasing government expenditure for the healthcare sector contributes to the market growth. According to the World Health Organization (WHO) report published in April 2018, approximately 30 million people are affected by rheumatic heart disease globally.
Despite the drivers, lack of awareness about the condition and limited healthcare facilities in emerging economies may hamper the growth of the market during the assessment period.
Oakrum Pharma, LLC and ANI Pharmaceuticals announced in February 2022 that the FDA approved a generic version of Cystadane1 (betaine anhydrous for oral solution) Powder in a 180-gm bottle, which was granted Competitive Generic Therapy (CGT) of 180 days of exclusivity.
Viatris Inc., the parent to Mylan Pharmaceuticals Inc., disclosed this information in February 2022 when it got the FDA’s approval on its Abbreviated New Drug Application (ANDA) for Cyclosporine Ophthalmic Emulsion 0.05%, which is the First generic version of Allergan’s Restasis® to be approved. There are no legal or regulatory barriers, and the company started operating right away.
In June 2023, New Zealand’s Associate Minister of Health for Pacific Peoples launched a further initiative aimed at reducing rheumatic fever. MP Barbara Edmonds said almost two-thirds of all rheumatic fever cases were among Pacific people. The Rheumatic Fever Roadmap 2023 - 2028 has been unveiled by Edmonds in Auckland this week to prevent, identify and treat rheumatic fever from around Aotearoa. Rheumatic fever is an autoimmune condition, according to Te Whatu Ora – New Zealand’s health authority. If untreated, strep throat can lead to rheumatic fever in at-risk children and young adults.
The American Society of Echocardiography (ASE) issued a new guideline document called “Recommendations on the Comprehensive Use of Echocardiography in Diagnosing and Therapeutic Intervention for ARF/RHD: A Report from the American Society of Echocardiography” in January, Journal of American Society Echocardiography Volume ___ issue ___. It had twenty-five ASE International Alliance Partners endorsements as an article that had been published by these societies. Among them, there is also a revised edition published with the title Recommendations for the Use of Echocardiography in Evaluating Rheumatic Heart Disease by the American Society of Echocardiography, out of all being updated to 2007 and 2009 guideline documents on valvular regurgitation or stenosis etiology, one of which was “Recommendations for the Use of Echocardiography in the Evaluation of Rheumatic Heart Disease: A Report from the American Society of Echocardiography”, under update. This new guideline is comprehensive and covers all uses of RHD.
Rheumatic Fever Market Segment Insights
The global rheumatic fever market has been segmented into diagnosis, treatment, distribution channel, and end-user.
Rheumatic Fever Diagnosis Insights
The market on the basis of diagnosis has been segmented into physical exam, blood test, electrocardiogram, and echocardiogram.
Rheumatic Fever Treatment Insights
The market, by treatment, has been segmented into pharmacotherapy and others. The pharmacotherapy segment is further segmented into antibiotics, anti-inflammatory medication, anticonvulsant medication, and others. Further, the anti-inflammatory medication segment has been segmented into aspirin, naproxen, and others.
Rheumatic Fever Distribution Channel Insights
The market, by distribution channel, has been segmented into retail pharmacies, hospital pharmacies, and others.
Rheumatic Fever End-User Insights
On the basis of end-user, the market has been segmented into hospitals and clinics, diagnostic centers, and others.
Rheumatic Fever Regional Insights
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rheumatic fever market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European rheumatic fever market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The rheumatic fever market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rheumatic fever market in the Middle East & Africa has been segmented into the Middle East and Africa.
Rheumatic Fever Market Top Key Players
Some of the key players in the global rheumatic fever market are:
- Bayer AG
- Abbott Laboratories
- Johnson & Johnson Services, Inc.
- F. Hoffman-La Roche Ltd.
- Novartis AG
- Pfizer, Inc.
- AstraZeneca
- Valeant Pharmaceuticals International, Inc.
- Eli Lilly and Company
Geographically, the Americas is anticipated to dominate the global rheumatic fever market owing to a well-developed healthcare sector, rising prevalence of cardiovascular diseases, and growing healthcare expenditure. According to the Centers for Disease Control and Prevention, approximately 610,000 people die of heart diseases in the US every year. Additionally, increasing awareness among the people regarding the disease and well-developed technology are likely to contribute to the growth of the market.
Europe is expected to hold the second largest position in the global rheumatic fever market. The market growth in this region is attributed to the growing prevalence of rheumatic heart disease, availability of funds for research, and increasing healthcare expenditure.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, growing occurrences of rheumatic fever, and increasing government funding for the healthcare sector.
On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to a well-developed healthcare sector and growing government initiatives for rheumatic heart disease. For instance, according to the RHD Global Status Report, 2015 to 2017, Egypt’s Rheumatic Heart Disease (RHD) programme trained 300 cardiologists and 1,500 primary healthcare physicians in rheumatic heart disease management in 2015. However, the market in the African region is expected to propel owing to the rising prevalence of rheumatic heart disease and increasing government initiatives for the prevention of rheumatic fever.
Rheumatic Fever Market Segment Analysis
Rheumatic Fever Diagnosis Outlook
- Physical Exam
- Blood Test
- Electrocardiogram
- Echocardiogram
Rheumatic Fever Treatment Outlook
- Pharmacotherapy
- Antibiotics
- Anti-inflammatory Medication
- Aspirin
- Naproxen
- Others
- Anticonvulsant Medication
- Others
- Others
Rheumatic Fever Distribution Channel Outlook
- Retail Pharmacies
- Hospital Pharmacies
- Others
Rheumatic Fever End-User Outlook
- Hospitals and Clinics
- Diagnostic Centers
- Others
Rheumatic Fever Regional Outlook
- Americas
-
- North America
- US
- Canada
- South America
- Europe
-
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
-
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
-
- Middle East
- Africa
Intended Audience
- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Diagnostic Laboratories
- Government Research Institute
- Academic Institutes and Universities
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
